Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT02703272
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 280
- Registration Number
- NCT02688140
- Locations
- 🇩🇪
OSHO study group, Multiple Locations, Germany
🇩🇪SAL study group, Multiple Locations, Germany
🇳🇱HOVON study group, Multiple Locations, Netherlands
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Emory University
- Registration Number
- NCT02680951
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT02652871
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Steven E. Coutre
- Target Recruit Count
- 2
- Registration Number
- NCT02635074
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 153
- Registration Number
- NCT02632708
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02626338
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Houston Methodist, Houston, Texas, United States
🇺🇸University of Arkansas, Little Rock, Arkansas, United States
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT02560025
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT02527174
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02464657
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.